Eric Dube, Travere Therapeutics CEO
Travere misses primary endpoint in PhIII for rare kidney disease but the company is still considering a 'path forward'
Travere Therapeutics’ drug sparsentan didn’t hit the primary endpoint in a Phase III study in a rare kidney disease, but neither the company nor analysts …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
